Objective To investigate the effect of Xingnaojing combined with Shengmai injection on the expression of CD62P, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in cerebral hemorrhage patients and its clinical efficacy.Methods A total of 152 patients, who were diagnosed with cerebral hemorrhage by symptoms and laboratory tests and admitted to the Department of Neurology of our hospital between April 2014 and October 2015, were randomly divided into treatment (n=78) and control (n=74) groups. Both groups were subjected to conventional therapy, with the addition of Xingnaojing combined with Shengmai injection for the treatment group. Changes in circulating CD62P, TNF-α, and IL-6 levels, as well as changes in the National Institute of Health Stroke Scale (NIHSS) and Activity of Daily Living Scale (ADL) scores, were compared between the treatment and control groups after 7 and 14 days of treatment.Results Circulating CD62P, TNF-α, and IL-6 were significantly lower in the treatment group than in the control group after 7 and 14 days of treatment (all P<0.05). However, NIHSS scores were significantly lower and ADL scores were significantly higher in the treatment group than in the control group after 7 and 14 days of treatment (P<0.05).Conclusions Xingnaojing combined with Shengmai injection may protect the function of the nervous system in cerebral hemorrhage patients, probably by reducing platelet activation (CD62P) and TNF-α and IL-6 expression.